HRP20030147B1 - Vaccination aganist host cell-associated herpesviruses - Google Patents

Vaccination aganist host cell-associated herpesviruses

Info

Publication number
HRP20030147B1
HRP20030147B1 HR20030147A HRP20030147A HRP20030147B1 HR P20030147 B1 HRP20030147 B1 HR P20030147B1 HR 20030147 A HR20030147 A HR 20030147A HR P20030147 A HRP20030147 A HR P20030147A HR P20030147 B1 HRP20030147 B1 HR P20030147B1
Authority
HR
Croatia
Prior art keywords
host cell
aganist
vaccination
genome
virus
Prior art date
Application number
HR20030147A
Other languages
English (en)
Croatian (hr)
Inventor
Fehler Frank
Osterrieder Klaus
Original Assignee
Lohmann Animal Health Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Animal Health Gmbh & Co. Kg filed Critical Lohmann Animal Health Gmbh & Co. Kg
Publication of HRP20030147A2 publication Critical patent/HRP20030147A2/hr
Publication of HRP20030147B1 publication Critical patent/HRP20030147B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR20030147A 2000-08-03 2001-08-01 Vaccination aganist host cell-associated herpesviruses HRP20030147B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202757A EP1178111A1 (en) 2000-08-03 2000-08-03 Vaccination against host cell-associated herpesviruses
PCT/EP2001/008893 WO2002012288A2 (en) 2000-08-03 2001-08-01 Vaccination against host cell-associated herpesviruses

Publications (2)

Publication Number Publication Date
HRP20030147A2 HRP20030147A2 (en) 2005-04-30
HRP20030147B1 true HRP20030147B1 (en) 2011-10-31

Family

ID=8171884

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030147A HRP20030147B1 (en) 2000-08-03 2001-08-01 Vaccination aganist host cell-associated herpesviruses

Country Status (24)

Country Link
US (1) US9073979B2 (enExample)
EP (2) EP1178111A1 (enExample)
JP (1) JP4313036B2 (enExample)
KR (1) KR100633180B1 (enExample)
CN (2) CN102151333A (enExample)
AT (1) ATE412055T1 (enExample)
AU (2) AU2001291716B2 (enExample)
BR (1) BRPI0112989B1 (enExample)
CA (1) CA2417923C (enExample)
CZ (1) CZ303904B6 (enExample)
DE (1) DE60136278D1 (enExample)
EA (1) EA010721B1 (enExample)
ES (1) ES2315306T3 (enExample)
HR (1) HRP20030147B1 (enExample)
HU (1) HU228262B1 (enExample)
IL (2) IL154250A0 (enExample)
MX (1) MXPA03001027A (enExample)
NO (1) NO332621B1 (enExample)
NZ (1) NZ524066A (enExample)
PL (1) PL207958B1 (enExample)
PT (1) PT1307565E (enExample)
UA (1) UA84667C2 (enExample)
WO (1) WO2002012288A2 (enExample)
ZA (1) ZA200300842B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
CA2558586A1 (en) * 2004-03-05 2005-09-15 The Research Foundation For Microbial Diseases Of Osaka University Recombinant varicella-zoster virus
US9273326B2 (en) 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
US20080226677A1 (en) * 2004-05-06 2008-09-18 Yasuko Mori Recombinant virus vector for gene transfer into lymphoid cells
RU2585961C9 (ru) 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
DK2516629T3 (en) 2009-12-21 2016-07-04 Brigham & Womens Hospital Inc Herpes simplex virus vaccines
JP6055776B2 (ja) * 2010-11-24 2016-12-27 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法
IN2014CN02681A (enExample) * 2011-10-21 2015-07-03 Intervet Int Bv
JP6199878B2 (ja) * 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
CN105641692A (zh) * 2015-12-30 2016-06-08 暨南大学 单纯疱疹病毒ⅰ型基因重组减毒活疫苗及其制备方法
CN105597095A (zh) * 2015-12-30 2016-05-25 暨南大学 一种应用微载体培养Vero细胞制备基因缺失减毒疫苗的方法
CN105561303B (zh) * 2015-12-30 2019-04-05 暨南大学 单纯疱疹病毒i型ul5基因缺失的dna疫苗的制备方法
EP3519427A4 (en) 2016-09-28 2020-03-11 Genocea Biosciences Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES
EP3658581A1 (en) * 2017-07-24 2020-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat hcmv related diseases
WO2019121888A1 (en) * 2017-12-20 2019-06-27 Intervet International B.V. Improved diluent for cell-associated alphaherpesvirus vaccine
WO2019152821A1 (en) 2018-02-05 2019-08-08 The Brigham And Women's Hospital, Inc. Recombinant herpes simplex virus-2 expressing glycoprotein b and d antigens

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0522535A1 (en) * 1991-07-09 1993-01-13 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant marek's disease virus, process for preparing the same and vaccine containing the same
WO1998053854A1 (en) * 1997-05-29 1998-12-03 The Research Foundation Of State University Of New York Antigen delivery system
WO1999006582A1 (de) * 1997-08-01 1999-02-11 Koszinowski Ulrich H Rekombinanter vektor, der infektiöse virale genomsequenzen mit einer grösse von mehr als 100 kb enthält, verfahren zu seiner herstellung und verwendung zur mutagenese der viralen sequenzen
WO2000026396A1 (en) * 1998-10-30 2000-05-11 The Murdoch Institute A method of recombination and agents useful for same
WO2000035476A1 (en) * 1998-12-14 2000-06-22 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute In ovo vaccination of 1 type marek's disease virus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959466A (en) * 1974-04-15 1976-05-25 The Wistar Institute Highly attenuated cytomegalovirus vaccine and production thereof
GB8821441D0 (en) 1988-09-13 1988-10-12 Animal Health Inst Viral vectors
EP0486106A3 (en) 1990-11-16 1992-12-23 Akzo N.V. Marek's disease virus vaccine
JP3675569B2 (ja) 1995-04-28 2005-07-27 日本ゼオン株式会社 組み換えウイルス及びそれよりなるワクチン
EP0837929A2 (en) 1995-07-07 1998-04-29 Nippon Zeon Co., Ltd. Marek's disease virus genes and their use in vaccines for protection against marek's disease
EP1038952A3 (en) 1998-12-09 2001-06-27 Pfizer Products Inc. Processes for preparation of Marek's Disease Virus using continuous avian cell lines
US6299882B1 (en) 1999-04-09 2001-10-09 Schering Corporation UL54.5 of Marek's disease virus (MDV)
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0522535A1 (en) * 1991-07-09 1993-01-13 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant marek's disease virus, process for preparing the same and vaccine containing the same
WO1998053854A1 (en) * 1997-05-29 1998-12-03 The Research Foundation Of State University Of New York Antigen delivery system
WO1999006582A1 (de) * 1997-08-01 1999-02-11 Koszinowski Ulrich H Rekombinanter vektor, der infektiöse virale genomsequenzen mit einer grösse von mehr als 100 kb enthält, verfahren zu seiner herstellung und verwendung zur mutagenese der viralen sequenzen
WO2000026396A1 (en) * 1998-10-30 2000-05-11 The Murdoch Institute A method of recombination and agents useful for same
WO2000035476A1 (en) * 1998-12-14 2000-06-22 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute In ovo vaccination of 1 type marek's disease virus

Also Published As

Publication number Publication date
NO20030524D0 (no) 2003-02-03
EP1307565A2 (en) 2003-05-07
WO2002012288A3 (en) 2002-04-11
HUP0302664A2 (hu) 2003-11-28
CN1503843A (zh) 2004-06-09
CN102151333A (zh) 2011-08-17
CA2417923C (en) 2010-06-29
IL154250A (en) 2013-07-31
UA84667C2 (ru) 2008-11-25
CZ2003324A3 (cs) 2003-06-18
WO2002012288A2 (en) 2002-02-14
AU9171601A (en) 2002-02-18
KR100633180B1 (ko) 2006-10-11
EP1178111A1 (en) 2002-02-06
PT1307565E (pt) 2009-01-28
AU2001291716B2 (en) 2007-06-07
BRPI0112989B1 (pt) 2015-09-08
DE60136278D1 (de) 2008-12-04
EA200300215A1 (ru) 2003-08-28
PL207958B1 (pl) 2011-02-28
NZ524066A (en) 2004-11-26
ATE412055T1 (de) 2008-11-15
BR0112989A (pt) 2003-09-09
US20030165537A1 (en) 2003-09-04
KR20030036657A (ko) 2003-05-09
MXPA03001027A (es) 2004-02-26
JP2004505993A (ja) 2004-02-26
AU2001291716B8 (en) 2002-02-18
IL154250A0 (en) 2003-09-17
PL365190A1 (en) 2004-12-27
ZA200300842B (en) 2004-04-30
HU228262B1 (en) 2013-02-28
JP4313036B2 (ja) 2009-08-12
US9073979B2 (en) 2015-07-07
EP1307565B1 (en) 2008-10-22
ES2315306T3 (es) 2009-04-01
EA010721B1 (ru) 2008-10-30
CA2417923A1 (en) 2002-02-14
CZ303904B6 (cs) 2013-06-19
HUP0302664A3 (en) 2004-10-28
HRP20030147A2 (en) 2005-04-30
NO20030524L (no) 2003-04-03
NO332621B1 (no) 2012-11-19

Similar Documents

Publication Publication Date Title
Gahn et al. An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene
RU2014120471A (ru) Конструкции рекомбинантного непатогенного вируса болезни марека, кодирующие антигены вируса инфекционного ларинготрахеита и вируса болезни ньюкасла
CA2260855A1 (en) Polynucleotide vaccine formula in particular against bovine respiratory pathology
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
DE69024809D1 (de) Herpes simplex virus typ 1 mutante
DK1252323T3 (da) Virus-stammer til den onkolytiske behandling af cancer
HUP9902790A2 (hu) Madarakban alkalmazható polinukleotid-vakcinakészítmények
BR9711998A (pt) Herpesvìrus saimiri como vetor viral.
He et al. Genomic analysis of a Chinese MDV strain derived from vaccine strain CVI988 through recombination
DK1356062T3 (da) Frembringelse af rekombinanter af kunstigt gærkromosom af human cytomegalovirus
Nagesha et al. Analysis of the nucleotide sequence of five genes at the left end of the unique short region of the equine herpesvirus 4 genome
Rijsewijk et al. Spontaneous BHV1 recombinants in which the gI/gE/US9 region is replaced by a duplication/inversion of the US1. 5/US2 region
ES2201060T3 (es) Virus del herpes equino recombinante.
ATE454453T1 (de) Virale nukleotidsequenzen
TR200102168T2 (tr) BHV-1 geni silinmiş virüs aşısı.
Kuo et al. Herpes simplex virus type 1 genes in human mononuclear cells and affecting cell‐mediated immunity
Becker Live Herpesvirus Vaccines: Serendipity or Engineering of the Virus Genome
Marcello et al. 141 The nine carboxyterminal aminoacids of HSV ribonucleotide reductase fused to an heterologous protein are capable of binding the large subunit of the enzyme
種子野章 et al. Immunological properties of the cell-associated live infectious laryngotracheitis virus.
Paterson Expression and Characterization of Four Herpes Simplex Virus Type 1 Gene Products Required for the Replication of Viral DNA
Zapata et al. Correlaciones moleculares, clínicas y serológicas de los alfaherpesvirus de Rumiantes, con especial referencia al HVB-1

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20120713

Year of fee payment: 12

PBON Lapse due to non-payment of renewal fee

Effective date: 20130801